Introduction {#s1}
============

Glucose transporter type 1 deficiency syndrome (GLUT1-DS) is caused by impaired glucose transport across the blood--brain barrier and into astrocytes, leading to cerebral energy deficiency.[@R1] GLUT1-DS is caused by mutation in the *SLC2A1* gene encoding the glucose transporter GLUT1. The phenotype typically comprises psychomotor retardation and permanent motor disorders, associated with paroxysmal manifestations including seizures and non-epileptic paroxysmal episodes.[@R1] [@R2] With age, seizures tend to become less prominent, whereas the frequency of non-epileptic paroxysmal episodes increases.[@R3] In patients with milder forms of the disease, paroxysmal movement disorders, especially dyskinesia, may be the main or the sole manifestations of the disease and can occur at any age.[@R3] [@R4] Ketogenic diets, which provide ketone bodies to the brain and compensate for the lack of glucose, represent the standard of care in GLUT1-DS[@R1] [@R5] and are efficient on seizures control but less on movement disorders.[@R2] Moreover, many patients, especially adolescents and adults, have difficulties in complying with the difficult constraints of these long-term diets and their side effects.

Triheptanoin is an odd-chain triglyceride with anaplerotic properties---that is, replenishing the pool of metabolic intermediates in the Krebs cycle. Unlike even-chain fatty acids metabolised to acetyl-CoA only, triheptanoin can indeed provide both acetyl-CoA and propionyl-CoA, two key carbon sources for the Krebs cycle. We showed that triheptanoin was able to produce C5-ketone bodies and restore energy metabolism and neurotransmission in pyruvate carboxylase (PC) deficiency, a severe metabolic disease that affects anaplerosis in the brain.[@R6] Recently, we demonstrated that triheptanoin is able to correct bioenergetics in the brain of patients with Huntington\'s disease (HD), a neurodegenerative disease associated with brain energy deficit.[@R7] Here, we wished to obtain a proof-of-concept of the therapeutic effect of triheptanoin in patients with GLUT1-DS with non-epileptic paroxysmal manifestations for whom a ketogenic diet was not a therapeutic option.

Subjects and methods {#s2}
====================

Participants were enrolled in an interventional clinical protocol (NCT02014883) at the Pitié-Salpêtrière Hospital promoted by INSERM and approved by the local ethical committee. All participants and/or their legal guardians signed a written informed consent before participating in the study. Four children and four adults were enrolled with GLUT1-DS as defined by low cerebrospinal fluid to blood glucose ratio and a *SLC2A1* missense mutation predicted to be pathogenic by prediction software programs. Patients had a chronic history of non-epileptic paroxysmal motor disorders, especially paroxysmal exercise-induced dyskinesia, non-kinesigenic dyskinesia, limb weakness, headache, drowsiness and dysphoria. Three patients also presented a mild cognitive deficit. All patients were on a normal diet prior to their enrolment as either they objected to or did not tolerate ketogenic diets. The study was divided into three phases of 2 months each (baseline, treatment and withdrawal). A trained dietician determined the patient\'s caloric intake and adjusted their daily menus so that their diet remained isocaloric when triheptanoin was introduced. During the treatment phase, each patient was required to ingest 1 g/kg body-weight of triheptanoin per day, divided into 3--4 intakes during meals.

During each study phase, the patients and/or their legal guardians had to fill a comprehensive patient diary to record all motor (seizure, abnormal movement, body stiffness, body weakness, abnormal speech) and non-motor (headache, lethargy, mood swing) paroxysmal events (see online supplementary table e1). The approximate duration of each episode was recorded (minutes). At each visit, recordings of all paroxysmal events were reviewed with the evaluating physician and items were grouped into motor and non-motor episodes. At each visit, patients were also evaluated with a 6 min walk test (6MWT), a nine-hole pegboard test (9HPT) and the clinical global impression-improvement scale (CGI-I). The 6MWT was performed in a corridor, between two cones separated by a distance of 25 m, in order to get the maximal distance covered during 6 min by walking. Both the dominant and non-dominant hands were tested twice during the 9HPT and the best score for each hand was recorded. Blood samples were collected after an overnight fast for standard analyses, plasma C3-carnitine and C5-ketone bodies.[@R6]

To assess the effect of triheptanoin on brain energy metabolism, functional ^31^P-NMR spectroscopy (f-MRS) was performed at 3 T at the end of each study phase in patients \>15 years old (n=5). We targeted the visual cortex using a surface coil as it is easily stimulated and is close to the scalp, allowing an increased sensitivity to the surface coil. Furthermore, visual stimulation results in a large increase in glucose uptake and cerebral blood flow.[@R8] Data were collected for 4 min at rest, 8 min during visual activation, 8 min after stimulation and analysed as described.[@R7] [@R9] The ratio of inorganic phosphate over phosphocreatine (Pi/PCr) was calculated to determine the brain response to cortical activation as it is directly related to the ADP levels which regulate mitochondrial oxidative metabolism.[@R10]

Paired t tests were used for plasma analyses before and after treatment. For clinical parameters, Friedman tests were used to test the global hypothesis that all study phases were equal. If significant, Wilcoxon signed-rank tests were applied for pairwise phase comparisons with an α of 0.05. For the Pi/PCr ratio, repeated measures analysis of variance (ANOVA) were used to test the global hypothesis that all time points (rest, activation and recovery) were equal. If significant, paired t tests were applied for pairwise time comparisons with an α of 0.05.

Results {#s3}
=======

Triheptanoin was well tolerated in all patients and none experienced gastrointestinal symptoms. Two patients were considered not compliant with the study as they consumed less than 50% of the recommended dose of triheptanoin and they (or their legal guardians) regularly omitted to fill the patient diary: a 13-year-old patient with mild cognitive delay who experienced only a few paroxysmal manifestations prior to the study, and a 23-year-old patient who was in denial of his disease. Owing to the small sample size, a per-protocol analysis was performed in the six patients who completed the study (see online supplementary table e2).

During the baseline phase, patients with GLUT1-DS experienced a mean of 30.8 (±27.7, 10--85) paroxysmal manifestations over 2 months, including 16.5 (±19.1, 1--54) motor episodes. When treated with triheptanoin for 2 months, paroxysmal manifestations dropped to a mean of 2.8 (±2.9, 0--7), including 2.2 (±2.6, 0--7) motor episodes (p=0.028, [figure 1](#JNNP2015311475F1){ref-type="fig"}A), representing overall a 90% symptoms reduction. Two patients became free from paroxysmal manifestations ([table 1](#JNNP2015311475TB1){ref-type="table"}). Although not significant, triheptanoin tended to also reduce the mean duration of the remaining motor episodes---59±44 min at baseline compared to 10±10 min with triheptanoin, p=0.224. On the patient-rated CGI-I scale, all patients reported a clear improvement when treated ('much improved'). Conversely, during the 2-month withdrawal phase, patients experienced a mean of 24.2 (±21.9, 5--63) paroxysmal manifestations, including 12.5 (±14.5, 1--40) motor episodes (p=0.043, [figure 1](#JNNP2015311475F1){ref-type="fig"}A). On the patient-rated CGI-I scale, five out of six patients reported a clear worsening during withdrawal ('much worse'). The patients' performance on the 6WMT and 9HPT was unchanged along the different phases of the study ([table 1](#JNNP2015311475TB1){ref-type="table"}). On study completion, all patients wished to continue treatment with triheptanoin.

###### 

Main characteristics of patients with GLUT1-DS during the baseline, treatment and withdrawal phases

                    Patients   Mean                                    
  ----------------- ---------- ------- ------- ------- ------- ------- -------
  Sex               F          F       M       M       M       M       
  Age               23         20      7       14      16      47      21.2
  Baseline                                                             
   Total events     10         20      13      26      31      85      30.8
   Motor events     6          16      10      1       12      54      16.5
   6MWT (m)         502        558     458     514     471     504     501
   9HPT(D/ND) (s)   17/18      18/23   19/21   15/17   18/22   14/16   17/19
  Treatment                                                            
   Total events     4          7       5       0       1       0       2.8
   Motor events     2          7       3       0       1       0       2.2
   6MWT (m)         453        580     425     484     496     500     490
   9HPT(D/ND) (s)   17/19      17/20   19/19   17/21   17/18   15/18   17/19
  Withdrawal                                                           
   Total events     10         11      5       20      36      63      24.2
   Motor events     9          9       1       1       15      40      12.5
   6MWT (m)         532        528     461     496     475     510     500
   9HPT(D/ND) (s)   15/22      14/20   17/17   17/19   18/20   15/15   16/19

Total events: all motor and non-motor paroxysmal manifestations during each 2-month-phase. Motor events: all motor paroxysmal episodes during each 2-month-phase. 6MWT: Total distance walked (metres). 9HPT-D: the best score (seconds) obtained with the dominant hand. 9HPT-ND: best score (seconds) with the non-dominant hand.

GLUT1-DS, glucose transporter type 1 deficiency syndrome; 6MWT, 6 min walk test; 9HPT, nine-hole pegboard test

![(A) Number of total paroxysmal manifestations in patients with glucose transporter type 1 deficiency syndrome (GLUT1-DS) during the three phases of the study (baseline, treatment and withdrawal) of 2 months each. A significant reduction of non-epileptic paroxysmal manifestations was observed when patients were treated with triheptanoin for 2 months (\*p\<0.05). Of note, the total number of events was comparable between the baseline and withdrawal phases. Error bars represent SEM. (B) Changes in the inorganic phosphate and phosphocreatine (Pi/PCr) ratio from ^31^P-NMR spectroscopy (f-MRS) studies during the three phases of the study (baseline, treatment and withdrawal). During baseline, f-MRS showed an abnormal brain energy profile in patients with GLUT1-DS with no change in the Pi/PCr ratio during visual stimulation. After 2 months of treatment with triheptanoin, the profile was corrected and we observed an increase in the Pi/PCr ratio during visual stimulation followed by a decrease during recovery (\*p=0.021). Error bars represent SEM of within-subject differences using the method of Morey.](jnnp-2015-311475f01){#JNNP2015311475F1}

Compared to baseline, we observed a significant increase in plasma C3-carnitine (p=0.026) and C5-ketone bodies (p=0.008) on triheptanoin, reflecting its proper metabolism in the six compliant patients with GLUT1-DS. Conversely, the levels of triheptanoin metabolites were unchanged in the two non-compliant patients. During baseline, f-MRS showed an abnormal profile with no change in the Pi/PCr ratio during brain activation in patients with GLUT1-DS ([figure 1](#JNNP2015311475F1){ref-type="fig"}B), unlike what we reported in healthy individuals.[@R7] [@R9] After 2 months on triheptanoin, the bioenergetics profile normalised and repeated measures ANOVA were significant for the Pi/PCr ratio (p=0.014). We observed an increase in the Pi/PCr ratio during visual stimulation and a decrease during recovery using paired t tests (p=0.021). The increased Pi/PCr ratio during brain activation reflected a proportional elevation of ADP, allowing increased mitochondrial ATP production with triheptanoin. After treatment withdrawal, the f-MRS profile returned to its preintervention abnormal state ([figure 1](#JNNP2015311475F1){ref-type="fig"}B).

Discussion {#s4}
==========

Treatment with triheptanoin promptly reduced the number of non-epileptic paroxysmal manifestations in children and adults with GLUT1-DS. This marked clinical response was associated with a significant production of C5-ketone bodies and the normalisation of the f-MRS bioenergetics profile during brain activation. Despite the absence of a control group, the magnitude of the intervention effect (90% reduction) combined with the metabolic responses argues against a placebo effect. The lack of change in effort-based outcome measures tests such as the 6MWT and 9HPT during treatment further argues against a generalised placebo effect in this study.

Our current observation in GLUT1-DS is supported by previous preclinical and clinical studies. In animal models of diseases associated with brain energy deficiency, triheptanoin improved energy metabolism and motor deficits.[@R11] The first clinical response on neurological deficits with triheptanoin was reported in PC deficiency.[@R6] Triheptanoin was also able to correct the bioenergetics profile in the brain of early affected patients with HD.[@R7] Recently, a study in epileptic patients with GLUT1-DS showed a reduction in spike-waves on EEG about 90 min after taking antiepileptic drugs and triheptanoin.[@R15] Despite the small sample size, our study provides strong evidence for a sustainable clinical improvement with triheptanoin in GLUT1-DS together with a robust metabolic response using a validated biomarker of brain energy metabolism.[@R7] The confirmation of our data in a larger controlled study would hold promise for an alternative therapeutic approach in GLUT1-DS, especially for patients who cannot comply with the constraints of ketogenic diets.
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